Knowledge Base

Who should be responsible for the statistical analysis of clinical trials?

10 January 2024
2 min read

When the trial is completed, the supervisor will take back the original page of the case report form (the first page of the carbon free copy), and then the trial data will be input into the database and statistically analyzed by the biostatistician according to the statistical plan formulated before the trial. All subjects taking the trial drug will be analyzed (intention to treat analysis). Biostatisticians will provide formal statistical reports to report statistical results and attach all data tables. This report will be integrated into the final clinical trial summary report. The trial summary report is a detailed summary after the completion of the trial, including the test methods and materials, the description and evaluation of the results, statistical analysis, and the final obtained confirmatory, ethical, statistical and clinical evaluation report. The report should be written by the investigator. If it is a multicenter trial, it should be completed by the principal investigator. If the sponsor or the sponsor entrusts the contract research organization to write the report, the summary report shall be reviewed by the researcher, and the final draft shall be signed and dated to ensure the authenticity and accuracy of all the contents of the report.

Inspirna partners with German Merck KGaA to accelerate global development of RGX-202, also called Ompenaclid
Latest Hotspot
4 min read
Inspirna partners with German Merck KGaA to accelerate global development of RGX-202, also called Ompenaclid
9 January 2024
Inspirna teams up with German-based Merck KGaA to expedite the worldwide advancement of the drug Ompenaclid, known as RGX-202
Read →
TLR9 agonists: What They Are and How to Stay Updated on the Latest Research
TLR9 agonists: What They Are and How to Stay Updated on the Latest Research
9 January 2024
TLR9 agonists are molecules that activate the Toll-like receptor 9, enhancing immune response against microbial infections.
Read →
Debiopharm and Repare Therapeutics partner to explore combined PKMYT1 and WEE1 inhibitor use for cancer therapy
Latest Hotspot
3 min read
Debiopharm and Repare Therapeutics partner to explore combined PKMYT1 and WEE1 inhibitor use for cancer therapy
9 January 2024
Debiopharm is collaborating with Repare Therapeutics to investigate combining PKMYT1 and WEE1 inhibitors as a potential cancer treatment strategy.
Read →
Can subjects voluntarily withdraw from clinical trials?
Knowledge Base
2 min read
Can subjects voluntarily withdraw from clinical trials?
9 January 2024
According to the tenets of the declaration of Helsinki, subjects can withdraw from the trial at any time according to their own wishes without any reason.
Read →
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.